{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-25-000081","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.129567+00:00","generated_at":"2026-05-20T06:26:43.645339+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Centessa appoints Raphael Deferiere as Chief Accounting Officer","bullets":["Raphael Deferiere, CPA, appointed CAO effective May 27, 2025; John Crowley remains CFO.","Base salary of $400,000; annual bonus target 35% of base; option for 165,000 ADSs.","Option vests 25% at one year, then 36 equal monthly installments.","Mr. Deferiere was an Assurance Partner at Ernst & Young LLP (July 2017 – May 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-25-000081","json":"https://secwatch.observer/filing/0001847903-25-000081.json","markdown":"https://secwatch.observer/filing/0001847903-25-000081.md","text":"https://secwatch.observer/filing/0001847903-25-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000081/0001847903-25-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000081/cnta-20250527.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T06:26:43.645339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15eb2238de","claim":"John Crowley changed role as Chief Financial Officer at Centessa Pharmaceuticals plc.","evidence_excerpt":"Mr. Deferiere assumes the designation of principal accounting officer from John Crowley, who continues in his capacity as Chief Financial Officer and the Company’s principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000081/0001847903-25-000081-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"4dc4424826","claim":"Raphael Deferiere was appointed as Chief Accounting Officer at Centessa Pharmaceuticals plc.","evidence_excerpt":"On May 27, 2025, Centessa Pharmaceuticals plc (the “Company”) appointed Raphael Deferiere, CPA, as the Company’s Chief Accounting Officer and designated him as the Company’s principal accounting officer, each effective as of May 27, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000081/0001847903-25-000081-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}